All Type of News
Drug makers to face uphill battle over drug pricing
A report, released by the Health Insurance Review Assessment and Service on April 6, will mostly affect the revenue of pharmaceutical firms that sell antihypertensive drugs.
Based on the previous report of Professo...
Dong-A picked for Samchully Pharm takeover
Dong-A Pharmaceutical Co., the nation’s leading drug maker, has been picked as a preferred bidder for Samchully Pharm, according to market sources.
The sources also said Green Cross Corp. and Handok Pharm showed a ...
50 percent of pharmacists happy with separate drug dispensing from medical practice
Nearly 50 percent of pharmacists hold positive view on the current system of separating drug dispensing from medical practice, although the dispute of drug dispensing rights between doctors and pharmacists are still c...
Green Cross to develop cell-based pandemic vaccines
Green Cross Corp., said on April 6 that it intends to enhance the nation’s preparedness for an influenza pandemic by improving on existing vaccine production techniques using egg-based vaccine, through the development...
Hanmi releases bepotastine orally disintegrating tablets
Hanmi says it has recently launched bepotastine calcium (Potastin) in orally disintegrating tablets (ODT), an antihistamine for treatment of allergic rhinitis and uriticaria/puritus.
The ODT serves as an alternativ...
53 Hepsera generics waiting for regulatory approval
A total of 53 domestic drug makers are waiting for the green light of the Korea Food and Drug Administration to launch their generics for GlaxoSmithKline’s Hepsera (adefovir dipivoxil) as the re-examination period of ...
Zuellig salespersons lay idle
Zuellig Pharma Korea is now in a dilemma how to utilize its 30 salespersons involved in the over-the-counter (OTC) business of Boehringer Ingelheim.
The multinational drug manufacturer has signed a strategic partne...
Korea lags in research spending for development of anticancer drugs
Korea has lagged behind Japan and other developed nations in research and development (R&D) activities over the development of anticancer agents, undermining present and future growth potential, a local professor said...
KFDA to spend 5.5 billion won by 2013 to establish stem cell guidelines
No one can deny the fact that this research has great potential to find cures for intractable diseases.
Technologies developed from stem cell experiments are key to the development of the biotech industry, which i...
Cytokine therapies: novel approaches for clinical indications
Despite outstanding therapeutic promise and sound scientific rationale, most cytokine therapies have largely failed to establish clinical utility.
Nevertheless, SIS Immunology Research Center said it is now aiming...
